GlassScriptPhysician profile
Joseph Peter Oro
NPI 1720133887
$2,431.17
in general payments reported to CMS, 2019-2025
27 companies · $162 in 2025
The $162 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $74.26 · 2020: $152 · 2021: $614 · 2022: $452 · 2023: $639 · 2024: $338 · 2025: $162.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,139.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $416.04 | 2021-2025 | |
| Lilly USA, LLC | $370.10 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $235.90 | 2021-2024 | Xarelto |
| Amgen INC. | $231.97 | 2019-2024 | Evenity, Prolia |
| Grifols USA, LLC | $198.08 | 2019-2024 | Prolastin-C Liquid |
| Pfizer INC. | $188.15 | 2023-2024 | |
| Daiichi Sankyo INC. | $113.21 | 2020-2025 | Injectafer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.83 | 2021-2024 | Ofev, Jardiance |
| Astellas Pharma US INC | $73.16 | 2022-2024 | Myrbetriq, Veozah |
| Allergan, INC. | $71.47 | 2020-2021 | |
| Amarin Pharma, INC. | $62.74 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $54.73 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $51.21 | 2023 | Entyvio |
| Novartis Pharmaceuticals Corporation | $40.69 | 2021 | |
| Genentech USA, INC. | $37.67 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $29.46 | 2020 | |
| Abbott Laboratories | $27.93 | 2021 | |
| Novo Nordisk INC | $26.01 | 2021-2022 | |
| Axsome Therapeutics, INC. | $19.09 | 2022 | |
| Merck Sharp & Dohme LLC | $16.49 | 2025 | Rotateq, Capvaxive, Enflonsia |
| Glaxosmithkline, LLC. | $14.33 | 2024 | Shingrix |
| Actelion Pharmaceuticals US, INC. | $13.25 | 2024 | Uptravi, Opsumit |
| Astrazeneca Pharmaceuticals LP | $13.23 | 2021 | |
| Medtronic, INC. | $12.87 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $12.82 | 2021 | |
| Shire North American Group INC | $11.05 | 2019 | |
| Organon LLC | $7.69 | 2023 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Oro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.